Recent Publications

Hu WT , Howell JC, Ozturk T, Benameur K, Bassit LC, Ramonell R, Cashman KS, Pirmohammed S, Roback JD, Marconi VC, Yang I, Mac VV, Smith S, Sanz I, Wharton W, Lee FE, Schinazi RF (2020). Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. Emerging Infectious Diseases, https://doi.org/10.3201/eid2612.203334.

Misiura M, Howell JC, Wu J, Qiu D, Parker MW, Turner JA, Hu WT (2020). Race modifies default mode connectivity in Alzheimer’s disease. Translational Neurodegeneration, doi: 10.1186/s40035-020-0186-4.

Benameur K, Agarwal A, Auld SC, Butters MP, Webster AS, Ozturk T, Howell JC, Bassit LC, Velasquez A, Schinazi RF, Mullins ME, Hu WT (2020). Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, 2020. Emerging Infectious Diseases, 26(9), DOI: 10.3201/eid2609.202122.

Wharton W, Kollhoff AL, Gangishetti U, Verble DD, Upadhya S, Zetterberg H, Kumar V, Watts KD, Kippels AJ, Gearing M, Howell JC, Parker MW, Hu WT (2019). IL-9 alterations linked to Alzheimer’s disease in African Americans. Ann Neurol (86)3: 407-418.

Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WT (2019). CSF cytokines in aging, multiple sclerosis, and dementia. Front Immunology, doi: 10.3389/fimmu.2019.00480.

Ozturk T, Kollhoff A, Anderson AM, Howell JC, Loring DW, Waldrop-Valverde D, Franklin F, Letendre S, Tyor WR, Hu WT (2019). Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder. Sci Rep, doi 10.1038/s41598-019-45418-2.

Josephs KA, MacKenzie I, Frosch M, Bigio E, Neumann M, Arai T, Dugger BN, Ghetti B, Grossman M, Hasegawa M, Herrup K, Jellinger K, Revesz T, Vonsattel JP, Whitwell J, Wisniewski T, Hu WT (2019). LATE to the PART-y. Brain, 142(9):e47, doi: 10.1093/brain/awz224.

Niedzwiecki MM, Walker DI, Howell JC, Watts KD, Jones GP, Miller GM, Hu WT (2019). High-resolution metabolomic profiling of Alzheimer’s disease in plasma. Annals of Clinical and Translational Neurology, doi: 10.1002/acn3.50956.

French CD, Willoughby RE, Pan A, Wong SJ, Foley JF, Wheat LJ, Fernandez J, Encarnacion R, Ondrush JM, Fatteh N, Paez A, David D, Javaid W, Amzuta IG, Neilan AM, Robbins GK, Brunner AM, Hu WT, Mishchuk DO, Slupsky CM (2018). NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system. PLoS Negl Trop Dis, 12(2):e0007045.

Gangishetti U, Howell JC, Perrin RJ, Louneva N, Watts KD, Kollhoff A, Grossman M, Wolk DA, Shaw LM, Morris JC, Trojanowski JQ, Fagan AM, Arnold SE, Hu WT. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease. Alzheimer Research & Therapy (2018).

Kollhoff AL, Howell JC, Hu WT. Automation vs. experience: measuring Alzheimer's beta-amyloid 1-42 peptide in the CSF. Frontiers in Aging Neuroscience (2018).

Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, Watts KD, Paciotti S, Beccari T, Hu WT, Teunissen CE. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Annals of Clinical and Translational Neurology (2018).

Howell JC, Watts KD, Parker MW, Wu J, Kollhoff A, Wingo TS, Dorbin CD, Qiu D, Hu WT. Race modifies the relationship between cognition and CSF Alzheimer's disease biomarkers. Alzheimer Research & Therapy (2017).

Hu WT. No doubts about dementia advocacy. Lancet Psychiatry (2017).

Gendron TF, Daughrity LM,..., Hu WT,...,Glass JD,...Boylan KB, Petrucelli L. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72‐associated amyotrophic lateral sclerosis. Annals of Neurology (2017).

Gendron TF, Chew J,...,Hu WT,...,Glass JD,...,Boylan KB, Petrucelli L. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Science Translational Medicine (2017).

Hu WT, Watts KD, Tailor P, Nguyen TP, Howell JC, Lee RC, Seyfried NT, Gearing M, Hales CM, Levey AI, Lah JJ, Lee EK. CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease. Acta Neuropathologica Communications (2016).

Howell JC, Soyinka O, Parker M, Jarret TL, Roberts DL, Dorbin CD, Hu WT. Knowledge and attitudes in Alzheimer's disease in a cohort of older African Americans and Caucasians. American Journal of Alzheimer's Disease and Other Dementias (2015).

Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Gorostidi A, Bocchio L, Rami L, Hansson O, Sperling R, Engelborghs S, Vanderstichele H, Vandjick M, Hampel H, Teipl S, Albert M, Hu WT, Argiles JAM, De Deyn P, Hyman BT, Molinuevo JL, Frisoni G, Linazasoro G, Martinez-Lage P, de Leon M, van der Flier WM, Scheltens P, Shaw LM, Trojanowski JQ. Alzheimer’s disease CSF biomarker levels in cognitively normal subjects: multi-center study. Brain (2015).

Hu WT, Watts KD, Shaw LM, Howell JC, Trojanowski JQ, Basra S, Glass JD, Lah JJ, Levey AI. CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease? Annals of Clinical and Translational Neurology (2014).

Hu WT, Watts KD, Grossman M, Glass JD, Lah JJ, Hales C, Shelnutt M, Van Deerlin V, Trojanowski JQ, Levey AI. Reduced CSF p-Tau181 to Tau ratio is a biomarker of FTLD-TDP. Neurology (2013).